KKKatalin Keresztes

Katalin Keresztes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katalin Keresztes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 24 July 2005
      • Vol. 146  (30) , 1575-82

    [Association of Hodgkin lymphoma with Epstein-Barr virus in Hungary].

    by Katalin Keresztes, Beáta Bessenyei, Zoltán Szöllosi, Zoltán Beck, Zsófia Miltényi, Zoltán Nemes, Eva Oláh, Arpád Illés

    The occurrence of Epstein-Barr virus associated Hodgkin's lymphoma shows considerable variation from continent to continent and from country to country but in Hungary no such investigations have been performed so far. The authors analyse the presence of Epstein-Barr virus and the type of latency in histologic samples taken from Hodgkin's disease patients. They have analyzed the presence of virus using PCR, in situ hybridisation and immunohistochemistry. Out of 109 cases, 61 patients (56%) showed virus positivity by PCR while latent membrane protein 1 positivity was found in 47 cases (43%). As regards to gender ratio, 53% female and 58% male patients were virus positive by PCR. Epstein-Barr virus association did not show any alteration in children (1-14 years) when compared to that of adults (out of the 10 children 6 were positive by PCR). As regards to the lifestyle of Epstein-Barr virus positive patients, the incidence of smoking and the ratio of poor social conditions were significantly higher. Mixed cell type was the most frequent (65%) in these patients and Epstein-Barr PCR virus positivity was highest in this type (60%), primarily in age groups 11-20 and over 51 years. Epstein-Barr virus PCR positivity was 52% in nodular sclerosis (negative cases cumulated in the age group 15-30 years), other histologic subtypes could not be evaluated due to the small number of cases. On examining Hodgkin's lymphoma and Epstein-Barr virus association disease models, they could not categorize their patients into any of them though characteristic patient groups could be more or less observed also in their material. This may be explained by the socioeconomic differences of the population living under different economic conditions. These results indicate that Epstein-Barr infection may play an important role in the development of Hodgkin's lymphoma in Hungary, too.


  • Mediastinal Bulky Tumour in Hodgkin’s Disease and Prognostic Value of Positron Emission Tomography in the Evaluation of Post-Treatment Residual Masses

    by Katalin Keresztes, Zsolt Lengyel, Katalin Devenyi, Györgyi Vadasz, Zsofia Miltenyi, Arpad Illes

    Among the 193 patients (82 female, 111 male) treated primarily for Hodgkin’s disease at our clinic between 1990 and 2001 and followed up until 2003, 42 (22%) had mediastinal bulky tumours (MBTs) by the Cotswolds criteria. The rate of MBT diagnosis was significantly greater in the early stage of the disease, these patients were younger and – in contrast to the other group – they all received combined therapy. No significant differences were found in the overall and relapse-free survival rate in the two groups, but relapse and death rates were lower in the patients with bulky tumours. Of the total number of patients, 27 underwent a total of 31 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) examinations, mainly for the evaluation of post-treatment residual mass viability. In the 12 positive cases, the majority of patients received further therapy. During the mean follow-up time of 58 months (range 5–98 months) after obtaining negative results, progression of the disease was found in 2 cases 14 and 23 months later, respectively. Based on our results, we conclude that FDG-PET examinations show a good correlation with clinical follow-up results.


  • HCV and HGV infection in Hodgkin’s disease

    by Katalin Keresztes, Maria Takács, Margit Horányi, Zsófia Miltényi, Árpád Illés


    • 6 October 2002
      • Vol. 46  (3) , 247-51

    [Second malignancies in patients treated for Hodgkin's disease].

    by Katalin Keresztes, Zsófia Miltényi, Csilla András, Arpád Illés

    To analyse the incidence of second malignant neoplasms (SMN) in patients treated for Hodgkin s disease. Since 1(st) January 1967, 534 patients have received primary treatment for Hodgkin s disease and 470 cases have proved to be adequate for data analysis as regards to the development of SMN. SMN developed in 34 cases (7.2%), solid neoplasms were diagnosed in 26 cases (5.5%), lung neoplasms had the greatest incidence (11/26), hematologic malignancies were detected in 8 cases (1.7%), and non-Hodgkin s lymphoma was found in 5/8 cases. The mean age of patients with solid neoplasms was 38.1 years (18-59 years) at the diagnosis of Hodgkin s disease and the length of time until the diagnosis of SMN was 13.5 years (1-33 years). The mean age of patients with hematologic malignancies was 45 years (17-64 years), the latency period was 3.2 years (9 months-12 years). The therapies employed prior to the development of solid neoplasms involve: irradiation in 6 cases, chemotherapy in 8 and combined therapy in 12 cases. Out of the 20 cases of chemotherapy, CV/O/PP and its variants were used in 17 cases. Prior to the development of hematologic malignancies, 5 patients had received chemotherapy, 3 combined therapy and 7 patients CV/O/PP and its variants. The incidence of SMN, especially as regards to hematologic malignancies, was found lower in our patients as compared to literary data. This can be explained by the less intensive therapeutic techniques employed earlier as well as by shorter survival periods. As a result of better therapeutic management, the chances of long term survivals have increased and we should make every effort to avoid late complications such as SMN when planning therapeutic strategies.